Healthcare Growth Cap Conference
W New York
541 Lexington Ave
April 11, 2013 | New York, NY


Corner Image

Fill out my online form.

TimeTopic / Panel Track
7:30 - 8:30am

Networking Breakfast and Welcome by International Business Forum
Craig Simak, Chief Strategy Officer - IBF

Breakfast Hosted By:
Goodwin Proctor

8:30 - 9:20am

Opening Keynote Address

Transformative Innovation in Healthcare – A Large Payer’s View
Charles Saunders, MD, CEO - Healthagen, a division of Aetna

9:20 - 9:30am

Chairman’s Opening Remarks

Defining the Boundaries of Success for Growth Investing
Zubeen Shroff, Managing Director - Galen Partners

9:30 - 10:30am

Building Service Platforms of Scale for the New Healthcare Economy

This panel will address the opportunities and challenges that health care reform poses for entrepreneurs, executives and investors as they build services platforms, including:

  • The influx of newly-insured Americans and Medicaid expansion
  • Provider risk acceptance and ACO enablement
  • Physician consolidation and management

Tom Flynn, Partner - SVLS
Tracy Bahl, Special Advisor - General Atlantic
Jeff Crisan, Managing Director - Bain Capital Ventures
Kevin Cross, Executive Vice Chairman & Founder - WellNow Urgent Care
Bill Frack, Vice President - L.E.K.
Phil Kamp, CEO & Co-Founder - Valence Health
Malcolm Kostuchenko, Co-Founder and Managing Partner - Enhanced Equity Fund
Chad Moore, Director, Healthcare Investment Banking - Robert W Baird & Co

10:30 - 10:50am

Morning Networking Break

10:50 - 11:50am

The Evolution of Specialty Pharma and Diagnostics
Growth in this sector has changed over the last decade and will continue to evolve as a result of the following five factors:

  • Recent success with the Spec Pharma and Dx models has resulted in greater interest to pursue a "Buy & Build" strategy which is increasing competition for assets;
  • Increased demand for commercial assets by large and small companies as clinical programs have become increasingly expensive and risky;
  • Less willingness on the part of existing companies to divest commercial assets given the increased focus placed on EPS and fear of divesting something with potential;
  • Greater sophistication by sellers that has resulted in fewer proprietary deals and a more thorough auction process;
  • And finally there is the pressure of dealing with reimbursement

Adele Oliva, Partner - Quaker Partners
Patrick Heron, General Partner - Frazier Healthcare
Bhaskar Chaudhuri, Former President – Valeant Pharmaceuticals / Operating Partner – Frazier Healthcare
Samuel Saks, MD, Founding CEO - Jazz Pharmaceuticals
Martin Sobel, Director - Marwood
Declan Quirke, Managing Director & Head of Healthcare – Stifel

11:50 - 12:40pm

Digitizing the American Healthcare System
The Obama Administration has committed $27 Billion in Federal Spending to help Hospitals and Doctors Digitize!

This must-attend panel will highlight:

  • Downstream opportunities for HIT companies within the hospital/physician settings and the consumer/provider marketplace;
  • Products and services that will see rapid deployment and adoption within the provider community;
  • The next generation of software enabling more efficient patient care, a wave of consumer connectivity and data collection/sharing;

Michael Kluger, Managing Director - Altaris
Pete Hudson, CEO & Co-Founder - iTriage
Chris Powell, President - Precyse Solutions
Jacob Reider, Chief Medical Officer - Office of the National Coordinator for Health Information Technology

12:40 - 1:40pm

Luncheon with Presentation

1:10 - 1:40pm

How Chaos in Washington Will Affect Healthcare Companies and Create Opportunities

The next few years will likely see structural Medicare payment reforms that will mean reduced payments to downstream health care providers and, indirectly, the upstream manufacturers of drugs and devices, and suppliers.

This presentation will describe various reform scenarios and regulatory developments that will affect different market segments. For instance, we will look at what happens when payment models are modified, and what trends that will create in the life sciences and health care spaces. We will also discuss some of the Affordable Care Organization (“ACO”) models that are being implemented and some of the unintended consequences and incentives that are being created around them, such as the limitation of fraud & abuse laws to these entities and the incentives to collaborate to create market power vis-à-vis private payors, rather than the intended purpose to create efficiencies. We will also explore pricing programs and policies for drugs and other items, and how reforms will continue to impact manufacturers and suppliers.

Scot Hasselman, Partner - Reed Smith
Elizabeth Carder-Thompson, Partner - Reed Smith

1:40 - 2:40pm

Cultivating Rapid Growth for Emerging Medical Device Companies
This session will focus on the unique challenges and opportunities for "growth-stage" medical device companies. We will explore the transition from development businesses to those with approved products and need for successful product launch and commercial execution. We will also discuss corporate infrastructure needs, pre- and post-launch marketing strategies to facilitate meaningful growth, and finally what drives strategic interest and how to position a company for a successful exit.
Michael Wasserman, Managing Director - H.I.G. BioVentures
David Mayer, Partner - Abingworth
Hani Zeini, Founder & Chief Executive Officer - Sientra
Michael Mainelli, CEO – Stanmore
Dennis Crowley, VP of Corporate Development - Covidien
Bob Bicknese, Managing Director - Rothschild

2:40 - 3:30pm

Alternative Financing Strategies for Growth Stage Healthcare Companies
Ilan Nissan, Partner, Private Equity - Goodwin Procter
Greg Pachus, Managing Director, Healthcare and Life Science - Silicon Valley Bank
Matthew Reber, Principal - HealthCare Royalty Partners
Brad Smith, CFO - OmniGuide
Max Kahn, Investment Principal - Merck Global Health Innovation

3:30 - 4:00pm

Afternoon Networking Break

4:00 - 4:15pm

Strategies to Maximize Milestone and Escrow Collection Post-Transaction
Don Morrissey, Managing Director - Shareholder Representative Services

4:15 - 5:15pm

Risk Adjustment and Assessment in the Payor Universe
This panel will address three critical themes:

  • How payors are working to better understand their underlying members. What they are doing to assess risk and examples of strategies being utilized.
  • The impact of health reform. What effect will exchanges and “qualified health plans” have on the need to assess and adjust risk?
  • What do the next 3-5 years look like for payors? How more consumer directed healthcare and increased member engagement changes the equation.

Stuart Rosenthal, Partner, Business Law Department - Goodwin Procter
Shan Padda, Chairman & Chief Executive Officer - Health Integrated
Jack McCallum, CEO - CenseoHealth
Keith R. Dunleavy, M.D., President, CEO, and Chairman- Inovalon
Sundar Subramanian, Vice President and Partner - Booz & Company

5:15 - 6:30pm

Cocktails and Post-Conference Networking Reception

Subscribe to receive updates on conference speakers, agenda and registration opening:
Fill out my online form.
Join The IBF Community: